Modafinil and armodafinil in schizophrenia

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages

  Andrade, Chittaranjan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARMODAFINIL; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ALERTNESS; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DISEASE EXACERBATION; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEGATIVE SYNDROME; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SLEEP APNEA SYNDROME; WEIGHT GAIN;

EID: 84865772728     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12f07977     Document Type: Review

References (21)

1. Garnock-Jones KP, Dhillon S, Scott LJ. Armodafinil. CNS Drugs. 2009;23(9):793-803. doi:10.2165/1203290-0-0 PubMed
2. Makela EH, Miller K, Cutlip WD 2nd. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry. 2003;64(4):485-486. doi:10.408/JCP.v64n0420h PubMed
3. Saavedra-Velez C, Yusim A, Anbarasan D, et al. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009;70(1):104-112. doi:10.408/JCP.07r03982 PubMed
4. Freudenreich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009;70(12):1674-1680. doi:10.408/JCP.08m04683 PubMed
5. Roerig JL, Steffen KJ, Mitchell JE, et al. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol Psychiatry. 2009;65(7):607-613. doi:10.1016/j.biopsych.208.10.037 PubMed
6. Henderson DC, Freudenreich O, Borba CP, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res. 2011;130(1-3):53-56. doi:10.1016/j.schres.201.04. 09 PubMed
7. Kane JM, D'Souza DC, Patkar AA, et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry. 2010;71(11):1475- 1481. doi:10.408/JCP.09m05950gry PubMed
8. Arbabi M, Bagheri M, Rezaei F, et al. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology (Berl). 2012;220(3):591-598. doi:10.107/s0213-01-2513-z PubMed
9. Bobo WV, Woodward ND, Sim MY, et al. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2011;130(1-3):106-113. doi:10.1016/j.schres.201.05.015 PubMed
10. Scoriels L, Barnett JH, Soma PK, et al. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology (Berl). 2012;220(2):249-258. doi:10.107/s0213-01-2472-4 PubMed
11. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-137. doi:10.2165/0308-20342020-02 PubMed
12. Darwish M, Kirby M, Robertson P Jr, et al. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. doi:10.2165/0308-20847010-06 PubMed
13. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4-22. doi:10.1/j.1742-7843.207.017.x PubMed
14. Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516-525. doi:10.2174/13892010791636202 PubMed
15. Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother. 2010;44(5):863-870. doi:10.1345/aph.1M603 PubMed
16. Caccia S. Pharmacokinetics and metabolism update for some recent antipsychotics. Expert Opin Drug Metab Toxicol. 2011;7(7):829-846. doi:10.1517/1742525.201.575061 PubMed
17. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4(4):251-257. doi:10.371/CSRP.4.4.5 PubMed
18. Chwieduk CM, Scott LJ. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25(3):251-267. doi:10.2165/120670-0-0 PubMed
19. Darwish M, Bond M, Hellriegel ET, et al. Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study [published online ahead of print September 8, 2011]. J Clin Pharmacol. PubMed
20. Andrade C. Schizophrenia and smoking. J Clin Psychiatry. 2012;73(6):e725-e727. PubMed
21. P450 drug interaction table. Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine Web site. http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed June 22, 2012.